|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NINJ1 |
Gene summary for NINJ1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NINJ1 | Gene ID | 4814 |
| Gene name | ninjurin 1 | |
| Gene Alias | NIN1 | |
| Cytomap | 9q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q92982 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4814 | NINJ1 | GSM4909282 | Human | Breast | IDC | 1.94e-16 | 5.80e-01 | -0.0288 |
| 4814 | NINJ1 | GSM4909291 | Human | Breast | IDC | 1.00e-08 | 4.89e-01 | 0.1753 |
| 4814 | NINJ1 | GSM4909296 | Human | Breast | IDC | 1.93e-09 | 1.45e-01 | 0.1524 |
| 4814 | NINJ1 | GSM4909297 | Human | Breast | IDC | 2.96e-05 | -8.99e-02 | 0.1517 |
| 4814 | NINJ1 | GSM4909298 | Human | Breast | IDC | 1.08e-02 | 2.09e-01 | 0.1551 |
| 4814 | NINJ1 | GSM4909302 | Human | Breast | IDC | 1.88e-13 | 5.19e-01 | 0.1545 |
| 4814 | NINJ1 | GSM4909305 | Human | Breast | IDC | 1.70e-03 | 3.28e-01 | 0.0436 |
| 4814 | NINJ1 | GSM4909306 | Human | Breast | IDC | 9.17e-13 | 4.83e-01 | 0.1564 |
| 4814 | NINJ1 | GSM4909311 | Human | Breast | IDC | 1.50e-26 | -2.05e-02 | 0.1534 |
| 4814 | NINJ1 | GSM4909312 | Human | Breast | IDC | 1.87e-10 | 1.83e-01 | 0.1552 |
| 4814 | NINJ1 | GSM4909319 | Human | Breast | IDC | 5.10e-33 | 7.05e-02 | 0.1563 |
| 4814 | NINJ1 | GSM4909321 | Human | Breast | IDC | 1.87e-10 | 5.19e-02 | 0.1559 |
| 4814 | NINJ1 | brca2 | Human | Breast | Precancer | 1.44e-04 | 2.58e-01 | -0.024 |
| 4814 | NINJ1 | NCCBC14 | Human | Breast | DCIS | 6.54e-05 | 9.35e-02 | 0.2021 |
| 4814 | NINJ1 | P1 | Human | Breast | IDC | 1.42e-07 | -2.53e-01 | 0.1527 |
| 4814 | NINJ1 | DCIS2 | Human | Breast | DCIS | 3.97e-13 | -2.68e-01 | 0.0085 |
| 4814 | NINJ1 | LZE4T | Human | Esophagus | ESCC | 2.70e-13 | 4.28e-01 | 0.0811 |
| 4814 | NINJ1 | LZE7T | Human | Esophagus | ESCC | 6.02e-13 | 8.69e-01 | 0.0667 |
| 4814 | NINJ1 | LZE8T | Human | Esophagus | ESCC | 5.90e-08 | 6.02e-01 | 0.067 |
| 4814 | NINJ1 | LZE20T | Human | Esophagus | ESCC | 4.69e-02 | 3.32e-01 | 0.0662 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00509006 | Breast | Precancer | leukocyte migration | 47/1080 | 369/18723 | 2.82e-07 | 1.39e-05 | 47 |
| GO:00305956 | Breast | Precancer | leukocyte chemotaxis | 34/1080 | 230/18723 | 4.16e-07 | 1.89e-05 | 34 |
| GO:00603266 | Breast | Precancer | cell chemotaxis | 41/1080 | 310/18723 | 5.99e-07 | 2.55e-05 | 41 |
| GO:00507293 | Breast | Precancer | positive regulation of inflammatory response | 23/1080 | 142/18723 | 6.51e-06 | 1.81e-04 | 23 |
| GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
| GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
| GO:00313493 | Breast | Precancer | positive regulation of defense response | 33/1080 | 278/18723 | 6.79e-05 | 1.36e-03 | 33 |
| GO:00310995 | Breast | Precancer | regeneration | 25/1080 | 198/18723 | 1.91e-04 | 3.06e-03 | 25 |
| GO:0045766 | Breast | Precancer | positive regulation of angiogenesis | 23/1080 | 181/18723 | 3.09e-04 | 4.43e-03 | 23 |
| GO:1904018 | Breast | Precancer | positive regulation of vasculature development | 23/1080 | 181/18723 | 3.09e-04 | 4.43e-03 | 23 |
| GO:0045765 | Breast | Precancer | regulation of angiogenesis | 35/1080 | 342/18723 | 7.35e-04 | 8.80e-03 | 35 |
| GO:0070265 | Breast | Precancer | necrotic cell death | 11/1080 | 62/18723 | 7.54e-04 | 9.01e-03 | 11 |
| GO:1901342 | Breast | Precancer | regulation of vasculature development | 35/1080 | 348/18723 | 1.00e-03 | 1.12e-02 | 35 |
| GO:00622083 | Breast | Precancer | positive regulation of pattern recognition receptor signaling pathway | 8/1080 | 44/18723 | 3.31e-03 | 2.78e-02 | 8 |
| GO:0034123 | Breast | Precancer | positive regulation of toll-like receptor signaling pathway | 6/1080 | 28/18723 | 4.58e-03 | 3.53e-02 | 6 |
| GO:005090011 | Breast | IDC | leukocyte migration | 54/1434 | 369/18723 | 3.10e-06 | 1.15e-04 | 54 |
| GO:003059511 | Breast | IDC | leukocyte chemotaxis | 38/1434 | 230/18723 | 5.36e-06 | 1.76e-04 | 38 |
| GO:006032611 | Breast | IDC | cell chemotaxis | 46/1434 | 310/18723 | 1.13e-05 | 3.08e-04 | 46 |
| GO:003109912 | Breast | IDC | regeneration | 31/1434 | 198/18723 | 1.08e-04 | 2.03e-03 | 31 |
| GO:00313491 | Breast | IDC | positive regulation of defense response | 39/1434 | 278/18723 | 1.74e-04 | 2.95e-03 | 39 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NINJ1 | SNV | Missense_Mutation | rs762750806 | c.280N>A | p.Val94Met | p.V94M | Q92982 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A6-6782-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| NINJ1 | SNV | Missense_Mutation | rs755546683 | c.337G>A | p.Ala113Thr | p.A113T | Q92982 | protein_coding | tolerated(0.4) | possibly_damaging(0.532) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NINJ1 | SNV | Missense_Mutation | rs540681874 | c.388G>A | p.Val130Met | p.V130M | Q92982 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NINJ1 | SNV | Missense_Mutation | c.236N>A | p.Pro79His | p.P79H | Q92982 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| NINJ1 | SNV | Missense_Mutation | novel | c.386N>G | p.Ile129Ser | p.I129S | Q92982 | protein_coding | deleterious(0.02) | possibly_damaging(0.74) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NINJ1 | SNV | Missense_Mutation | novel | c.163N>A | p.Ala55Thr | p.A55T | Q92982 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NINJ1 | SNV | Missense_Mutation | novel | c.244N>A | p.Val82Ile | p.V82I | Q92982 | protein_coding | tolerated(0.21) | benign(0.056) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NINJ1 | SNV | Missense_Mutation | rs202187907 | c.368N>T | p.Thr123Met | p.T123M | Q92982 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| NINJ1 | SNV | Missense_Mutation | novel | c.412N>A | p.Ala138Thr | p.A138T | Q92982 | protein_coding | tolerated(0.05) | possibly_damaging(0.859) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NINJ1 | SNV | Missense_Mutation | novel | c.418N>A | p.Gly140Arg | p.G140R | Q92982 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |